Adding linafexor, a pulsatile oral FXR agonist (4 mg daily), to low-dose semaglutide (0.5 mg weekly) produced 6.17% weight loss versus 2.91% with semaglutide plus placebo at 16 weeks, a 3.26-point difference (95% CI -5.35 to -1.18). In this randomized phase 2 trial of 62 adults with obesity, treatment-naive type 2 diabetes and MASH, 53.3% versus 28.1% reached at least 5% weight loss. The combination also cut visceral fat by 13.85 cm2 and lowered ALT, GGT and serum bile acids, with comparable gastrointestinal side effects (23.3% vs 18.8%).
Semaglutide is known to work less well in type 2 diabetes, and pushing the dose raises nausea and lean-mass loss, so a dose-sparing partner with a different mechanism is an appealing idea. Bile-acid signalling through FXR offers one. Earlier non-pulsatile FXR agonists such as obeticholic acid were hampered by itching and unfavourable cholesterol effects, which this pulsatile design aims to avoid. Caveats are substantial. The trial is small, lasted only 16 weeks, and used a deliberately low semaglutide dose, so it cannot show the combination beats full-dose semaglutide, which typically achieves far larger losses. Liver histology and cardiovascular outcomes were not assessed, and lean-mass effects are not reported here. This is a preprint that has not been peer reviewed, and the details may change. It is hypothesis-generating and incremental, and larger, longer trials against standard dosing are needed before it affects practice. Adults with obesity, diabetes and fatty liver should keep proven options, such as titrated GLP-1 therapy, lifestyle change and glucose control, at the centre of treatment discussions.